The worldwide anal cancer market is anticipated to expand over the course of the projected period as a result of the rising prevalence of anal cancer and sexually transmitted diseases. As an illustration, data from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program in the United States indicate that the rate of new cases of anal cancer has increased from 1.7 per 100,000 people in 2008 to 1.8 per 100,000 people in 2018, and is anticipated to rise in line with this trend in the near future. The discovery of novel medicines for the treatment of anal cancer is likely to be the focus of rising research and development efforts over the course of the forecast period, which will propel market expansion. The market's major players are concentrating their efforts on anal cancer research and development, which is anticipated to fuel market expansion over the forecast period.
Coherent Market Insights predicts that the global Anal Cancer Market will be worth US$ 810.4 million in 2021 and grow at a CAGR of 6.3% during the forecast period (2021-2028).
Market Leaders in the Anal Cancer Industry:
1. Advaxis Inc.
The company was established in 2002 and has a primary office in Princeton, New Jersey. The goal of Advaxis Inc., an American firm, is to discover, develop, and market immunotherapies based on a technology platform that employs modified Listeria monocytogenes. In April 2022, Advaxis announced that The Oncologist would publish ADXS-PSA data. For the treatment of early prostate cancer, Advaxis announced the beginning of a phase 1 clinical trial for ADXS-504 in July 2021.
2. Eli Lilly and Company
The business was established in 1876, and it has its headquarters in Indianapolis, Indiana. Eli Lilly and Company (Lilly) is a healthcare organisation that is involved in the discovery, development, and commercialization of drugs for use in human healthcare. Lilly declared in October 2020 that it will purchase Disarm Therapeutics, which offers cutting-edge therapies for axonal degeneration. According to reports, the corporation will concentrate on developing treatments for autoimmune diseases, diabetes, obesity, and Alzheimer's in 2023.
3. LLC.
The business was founded in 1977 and is headquartered in Northbrook, United States of America. It is a type of business form that combines the limited liability of a corporation with the pass-through taxation of a partnership or sole proprietorship. As of July 2022, this business structure shielded shareholders from corporate liability.
4. GlaxoSmithKline plc
The company was founded in 2000 and has its headquarters in London, England. GSK produces medications for common diseases such as diabetes, cancer, parasites, and psychological health. Three unsolicited bids to buy the Consumer Healthcare business unit from Unilever were received by the company, the company stated in January 2022. GSK released encouraging Phase IIa research results for a novel, first-in-class potential drug for tuberculosis patients in November 2022.
5. Takeda Pharmaceutical Company Limited
The pharmaceutical company Takeda was founded in 1781 and became a corporation on January 29, 1925. Oncology, uncommon illnesses, neurology, gastroenterology, particle medicine, and immunizations are the company's primary areas of interest. In February 2023, Nimbus Therapeutics' TYK2 Program Subsidiary was fully acquired by Takeda. To develop a first-in-class treatment for celiac disease, Takeda entered a collaboration and licencing agreement with Zedira and Dr. Falk Pharma in October 2022.
6. Sun Pharmaceutical Industries Limited
Mumbai is home to Sun Pharmaceuticals, which was established in 1983. The company creates and markets active medicinal components and pharmaceutical formulations. Palbociclib, a breakthrough targeted medication for advanced breast cancer, is introduced by Sun Pharma in January 2023 with a special Patient Support Program. In March 2022, Sun Pharma launched its version of vortioxetine in India via an exclusive patent licence from Lundbeck.
7. Pfizer Inc.
The business was founded in 1849, and its main office is in Manhattan, New York City. Pfizer discovers and makes medications and vaccines for the medical specialties of immunology, cancer, heart, endocrinology, and neurology. Pfizer purchased Amplyx Pharmaceuticals in April 2021, along with the anti-fungal drug fosmanogepix (APX001). The business successfully acquired Biohaven Pharma in October 2022, along with its calcitonin gene-related peptide projects.
8. Novartis AG
Based in Basel, Swiss, and Cambridge, the U.S., Massachusetts, Novartis AG is a Swiss international pharmaceutical company (global research).The company Novartis AG was established in March, 1996. Products covered by Novartis include prescription medications, OTC medications, vaccinations, testing, prescription glasses, and veterinary medicine. A number of the following operations are carried out directly by Novartis through subsidiaries: Handling, Marketing, Operations, and Research.
9. Bayer AG
Bayer was established in 1863. Germany's Leverkusen is home to the company's headquarters. Pharmaceuticals, personal care items, fertilizers, agro - chemicals, and biotech products are just a few of Bayer's commercial specialties. In order to grow its female health industry, Bayer revealed in August 2020 that it had purchased KaNDy Therapeutics Ltd. The business stated in June 2021 that it has acquired Noria Therapeutics Inc. and PSMA Therapeutics Inc., acquiring access to several actinium-based experimental medicines for treating cancer.
Definition: Anal cancer is a condition where malignant (cancer) cells develop in the tissues of the anus. Human papillomavirus (HPV) infection is a factor in the majority of anal cancer cases. Anus or rectum bleeding or a tumour close to the anus are indications of anal cancer.
